logo

For the Inventor, By the Inventor

Durham, NC, United States of America

Jason Daniel Speake

This inventor holds 10 USPTO granted patents and 1 published patent application. Top assignees: Glaxosmithkline LLC, Smithkline Beecham Corporation, Anacor Pharmaceuticals, Inc.. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jason Daniel Speake. Retrieved from https://idiyas.com/inventor/jason-daniel-speake-jsqqmkwz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 20.0

Average Co-Inventor Count = 6.4

ph-index = 3

Forward Citations = 22(Granted Patents)


Location History:

  • Cary, NC (US) (2008 - 2014)
  • Research Triangle Park, NC (US) (2014)
  • Durham, NC (US) (2005 - 2023)

Company Filing History:

goldMedal4 out of 358 
 
Glaxosmithkline LLC
 patents
silverMedal3 out of 2,198 
 
Smithkline Beecham Corporation
 patents
bronzeMedal2 out of 70 
 
Anacor Pharmaceuticals, Inc.
 patents
4. 2 out of 8,748 
 
US Government as Represented by the Secretary of the Army
 patents
5. 1 out of 672 
 
Chiron Corporation
 patents
6. 1 out of 245 
 
Novartis Vaccines & Diagnostics, Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2005-2023

Loading Chart...
10 patents (USPTO):Explore Patents
1. 11691992 - Oxaborole analogs and uses thereof (2023-07-04),
2. 10961261 - Oxaborole analogs and uses thereof (2021-03-30),
3. 8822518 - Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction (2014-09-02),
4. 8633175 - Compounds as antagonists or inverse agonists at opioid receptors (2014-01-21),
5. 7939528 - Heterocycle compounds (2011-05-10),
6. 7625909 - Substituted quinazolinone compounds (2009-12-01),
7. 7442693 - Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors (2008-10-28),
8. 7368453 - Quinazolinone compounds with reduced bioaccumulation (2008-05-06),
9. 7285557 - Pyrimidinones as melanin concentrating hormone receptor 1 (2007-10-23),
10. 6884801 - Imidazoline derivatives as alpha-1A adrenoceptor ligands (2005-04-26),

Title: Jason Daniel Speake: Innovator in Pharmaceutical Research

Introduction

Jason Daniel Speake is a prominent inventor based in Durham, NC (US). He has made significant contributions to the field of pharmaceutical research, holding a total of 10 patents. His work primarily focuses on developing compounds that address diseases caused by parasites.

Latest Patents

Among his latest patents is the application titled "Oxaborole analogs and uses thereof." This application describes compounds, compositions, and methods that are useful in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of diseases caused by parasites. This innovative approach showcases his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Jason has worked with notable companies such as GlaxoSmithKline LLC and SmithKline Beecham Corporation. His experience in these organizations has allowed him to develop and refine his expertise in pharmaceutical innovations.

Collaborations

Jason has collaborated with esteemed colleagues, including Michael Joseph Bishop and David John Cowan. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

Jason Daniel Speake is a dedicated inventor whose work in pharmaceutical research has the potential to make a significant impact on public health. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…